<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:30:37Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10517884" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10517884</identifier>
        <datestamp>2023-09-25</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Target Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Target Oncol</journal-id>
              <journal-title-group>
                <journal-title>Targeted Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1776-2596</issn>
              <issn pub-type="epub">1776-260X</issn>
              <publisher>
                <publisher-name>Springer International Publishing</publisher-name>
                <publisher-loc>Cham</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10517884</article-id>
              <article-id pub-id-type="pmcid">PMC10517884</article-id>
              <article-id pub-id-type="pmc-uid">10517884</article-id>
              <article-id pub-id-type="pmid">37659025</article-id>
              <article-id pub-id-type="pmid">37659025</article-id>
              <article-id pub-id-type="publisher-id">987</article-id>
              <article-id pub-id-type="doi">10.1007/s11523-023-00987-1</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Summary of Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Motzer</surname>
                    <given-names>Robert J.</given-names>
                  </name>
                  <address>
                    <email>motzerr@mskcc.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Russo</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Grünwald</surname>
                    <given-names>Viktor</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tomita</surname>
                    <given-names>Yoshihiko</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zurawski</surname>
                    <given-names>Bogdan</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Parikh</surname>
                    <given-names>Omi</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Buti</surname>
                    <given-names>Sebastiano</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Barthélémy</surname>
                    <given-names>Philippe</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Goh</surname>
                    <given-names>Jeffrey C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ye</surname>
                    <given-names>Dingwei</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lingua</surname>
                    <given-names>Alejo</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lattouf</surname>
                    <given-names>Jean-Baptiste</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Albigès</surname>
                    <given-names>Laurence</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff13">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>George</surname>
                    <given-names>Saby</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff14">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shuch</surname>
                    <given-names>Brian</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff15">15</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sosman</surname>
                    <given-names>Jeffrey</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff16">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Staehler</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff17">17</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vázquez Estévez</surname>
                    <given-names>Sergio</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff18">18</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Simsek</surname>
                    <given-names>Burcin</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff19">19</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Spiridigliozzi</surname>
                    <given-names>Julia</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff20">20</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chudnovsky</surname>
                    <given-names>Aleksander</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff21">21</xref>
                  <xref ref-type="aff" rid="Aff25">25</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bex</surname>
                    <given-names>Axel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff22">22</xref>
                  <xref ref-type="aff" rid="Aff23">23</xref>
                  <xref ref-type="aff" rid="Aff24">24</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yrq0923</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Medicine, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY 10021 USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yrq0923</institution-id><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Surgery, Urology Service, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.410718.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0262 7331</institution-id><institution>Clinic for Urology, Clinic for Medical Oncology, </institution><institution>University Hospital Essen, </institution></institution-wrap>Essen, Germany </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.260975.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0671 5144</institution-id><institution>Department of Urology and Department of Molecular Oncology, </institution><institution>Niigata University Graduate School of Medical and Dental Sciences, </institution></institution-wrap>Niigata, Japan </aff>
                <aff id="Aff5"><label>5</label>Department of Outpatient Chemotherapy, Prof. Franciszek Łukaszczyk Oncology Centre, Bydgoszcz, Poland </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.440181.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0456 4815</institution-id><institution>Rosemere Cancer Centre, </institution><institution>Lancashire Teaching Hospitals NHS Trust, </institution></institution-wrap>Preston, UK </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k7wn190</institution-id><institution-id institution-id-type="GRID">grid.10383.39</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 0937</institution-id><institution>Department of Medicine and Surgery, </institution><institution>University of Parma, </institution></institution-wrap>Parma, Italy </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/008fdbn61</institution-id><institution-id institution-id-type="GRID">grid.512000.6</institution-id><institution>Medical Oncology Unit, </institution><institution>Institut de Cancérologie Strasbourg Europe, </institution></institution-wrap>Strasbourg, France </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03pnv4752</institution-id><institution-id institution-id-type="GRID">grid.1024.7</institution-id><institution-id institution-id-type="ISNI">0000 0000 8915 0953</institution-id><institution>ICON Research, </institution><institution>South Brisbane, and Queensland University of Technology, </institution></institution-wrap>Brisbane, QLD Australia </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00my25942</institution-id><institution-id institution-id-type="GRID">grid.452404.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0942</institution-id><institution>Department of Urology, </institution><institution>Fudan University Shanghai Cancer Center, </institution></institution-wrap>Shanghai, China </aff>
                <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05v9dz963</institution-id><institution-id institution-id-type="GRID">grid.511758.f</institution-id><institution>Instituto Médico Río Cuarto, </institution></institution-wrap>Río Cuarto, Argentina </aff>
                <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0410a8y51</institution-id><institution-id institution-id-type="GRID">grid.410559.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0743 2111</institution-id><institution>Department of Surgery-Urology, </institution><institution>CHUM-Centre Hospitalier de l’Université de Montréal, </institution></institution-wrap>Montreal, QC Canada </aff>
                <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.14925.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2284 9388</institution-id><institution>Department of Cancer Medicine, </institution><institution>Gustave Roussy, </institution></institution-wrap>Villejuif, France </aff>
                <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.240614.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 8635</institution-id><institution>Department of Medicine, </institution><institution>Roswell Park Comprehensive Cancer Center, </institution></institution-wrap>Buffalo, NY USA </aff>
                <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05t99sp05</institution-id><institution-id institution-id-type="GRID">grid.468726.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0486 2046</institution-id><institution>University of California, Los Angeles, </institution></institution-wrap>Los Angeles, CA USA </aff>
                <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/000e0be47</institution-id><institution-id institution-id-type="GRID">grid.16753.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2299 3507</institution-id><institution>Northwestern University Medical Center, </institution></institution-wrap>Chicago, IL USA </aff>
                <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Interdisciplinary Centre on Renal Tumors, </institution><institution>University of Munich, </institution></institution-wrap>Munich, Germany </aff>
                <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0416des07</institution-id><institution-id institution-id-type="GRID">grid.414792.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0579 2350</institution-id><institution>Hospital Universitario Lucus Augusti (HULA), EOXI de Lugo, Cervo e Monforte, </institution></institution-wrap>Lugo, Spain </aff>
                <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.419971.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0374 8313</institution-id><institution>Department of Global Biometrics and Data Science, </institution><institution>Bristol Myers Squibb, </institution></institution-wrap>Princeton, NJ USA </aff>
                <aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.419971.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0374 8313</institution-id><institution>Department of Oncology Late Clinical Global Drug Development, </institution><institution>Bristol Myers Squibb, </institution></institution-wrap>Princeton, NJ USA </aff>
                <aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.419971.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0374 8313</institution-id><institution>Department of Oncology, Clinical Development, </institution><institution>Bristol Myers Squibb, </institution></institution-wrap>Princeton, NJ USA </aff>
                <aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03xqtf034</institution-id><institution-id institution-id-type="GRID">grid.430814.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0674 1393</institution-id><institution>Department of Urology, </institution><institution>Netherlands Cancer Institute, </institution></institution-wrap>Amsterdam, The Netherlands </aff>
                <aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04rtdp853</institution-id><institution-id institution-id-type="GRID">grid.437485.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0439 3380</institution-id><institution>Department of Urology, </institution><institution>The Royal Free London NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1201</institution-id><institution>Division of Surgery and Interventional Science, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="GRID">grid.419849.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0447 7762</institution-id><institution>Present Address: Takeda Pharmaceuticals, </institution></institution-wrap>Boston, MA USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>2</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>2</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2023</year>
              </pub-date>
              <volume>18</volume>
              <issue>5</issue>
              <fpage>639</fpage>
              <lpage>641</lpage>
              <history>
                <date date-type="accepted">
                  <day>1</day>
                  <month>8</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).</p>
              </abstract>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100002491</institution-id>
                      <institution>Bristol-Myers Squibb</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Springer Nature Switzerland AG 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par2">This summary of research article summarizes Part A of the CheckMate 914 study [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
            </sec>
            <sec id="Sec2">
              <title>What is Renal Cell Carcinoma?</title>
              <p id="Par3">Renal cell carcinoma (RCC) is a type of cancer that begins in the lining of the nephrons in the kidney. Surgery is the standard treatment for people with early stages of RCC that is still within or next to the kidney and has not spread to elsewhere in the body. This surgery involves removing part of a kidney or kidney tumor (partial nephrectomy) or an entire kidney plus nearby tissue (radical nephrectomy). In about one-third of people who have surgery, RCC will come back within their kidneys or spread to other parts of the body.</p>
            </sec>
            <sec id="Sec3">
              <title>What did Part A of this Study Look at?</title>
              <p id="Par4">In Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34) people at high risk of RCC coming back after partial or radical nephrectomy received nivolumab plus ipilimumab (adjuvant therapy) to see if it lowered the risk of RCC returning compared with the risk of disease returning in similar patients receiving placebo.</p>
            </sec>
            <sec id="Sec4">
              <title>What were Researchers Investigating?</title>
              <p id="Par5">Researchers compared the median length of time people who received adjuvant nivolumab and ipilimumab survived and were free of the cancer returning after starting treatment (disease-free survival), with the median duration of disease-free survival in similar patients who received placebo after surgery. They also looked for side effects that people had with treatment.</p>
            </sec>
            <sec id="Sec5">
              <title>Who Participated in Part A of this Study?</title>
              <p id="Par6">In total, 816 people from 20 countries participated: 405 people were assigned to receive treatment with nivolumab (one 240-mg dose every 2 weeks for a total of 12 doses) plus ipilimumab (one 1-mg/kg dose every 6 weeks for a total of 4 doses), and 411 people were assigned to receive placebo administered in the same way as the active treatment.</p>
            </sec>
            <sec id="Sec6">
              <title>What did the Results of Part A of the Study Show?</title>
              <p id="Par7">The percentage of people who were living and cancer free at 24 months was 76% in the nivolumab plus ipilimumab group and 74% in the placebo group. Median disease-free survival was 50.7 months with placebo. Median disease-free survival with nivolumab plus ipilimumab could not be calculated because more than half of people assigned to this treatment were still cancer-free and living at the end of follow-up period (median follow-up was 37 months). The risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo.</p>
              <p id="Par8">In people treated with nivolumab plus ipilimumab, 89% had one or more side effects compared with 57% of people treated with placebo. The most common side effects related to nivolumab plus ipilimumab treatment (occurring in ≥ 15% of people) were pruritus, fatigue, rash, diarrhea, hyperthyroidism, and hypothyroidism. Side effects related to treatment that were severe or very severe occurred in 28% of people treated with nivolumab plus ipilimumab and 2% of people treated with placebo. There were four deaths (1%) in the nivolumab plus ipilimumab-treated group and none in the placebo-treated group that were considered related to treatment.</p>
            </sec>
            <sec id="Sec7">
              <title>What were the Main Conclusions?</title>
              <p id="Par9">Adjuvant therapy with nivolumab plus ipilimumab did not improve disease-free survival versus placebo in people with RCC who were at high risk of their cancer returning after partial or radical nephrectomy.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgements</title>
              <p>Summary prepared by Christina McManus, PhD, at Envision Pharma Group Limited and funded by Bristol Myers Squibb. Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by Memorial Sloan Kettering Cancer Center Support Grant (Core Grant, number P30 CA008748).</p>
            </ack>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1" notes-type="funding">
                <title>Funding</title>
                <p id="Par10">This study was sponsored by Bristol Myers Squibb and Ono Pharmaceutical.</p>
              </notes>
              <notes id="FPar2" notes-type="COI-statement">
                <title>Conflict of interest</title>
                <p id="Par11">Please see the original publication [<xref ref-type="bibr" rid="CR1">1</xref>] for full author disclosure information.</p>
              </notes>
              <notes id="FPar3">
                <title>Ethics approval, availability of data and material, and coding availability</title>
                <p id="Par121">Not applicable.</p>
              </notes>
              <notes id="FPar4" notes-type="author-contribution">
                <title>Author contribution</title>
                <p id="Par13">All authors had the opportunity to review this summary publication.</p>
              </notes>
              <notes id="FPar40">
                <title>Consent for publication</title>
                <p id="Par130">All authors had final responsibility for the decision to submit for publication.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>Reference</title>
              <ref id="CR1">
                <label>1.</label>
                <mixed-citation publication-type="other">Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023;401(10379):821–32. 10.1016/S0140-6736(22)02574-0 (The original publication is available at: <ext-link ext-link-type="uri" xlink:href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02574-0/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02574-0/fulltext</ext-link>).</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
